News & Insights

Gunderson Dettmer releases the 2024 Venture Capital Report, analyzing data collected from the thousands of venture financing transactions in which the firm has represented clients

BioPharma's article on the biotechnology sector's notable resurgence in IPOs quotes Gunderson Boston partner Tim Ehrlich.

Gunderson Dettmer hosted the Tackling the Lifecycle of Affinivax: From Inception to Exit webinar discussing Affinivax’s $3.3 billion acquisition by GSK.

Gunderson Dettmer is co-sponsoring the Longwood Healthcare Leaders Boston CEO Summit 2025, a two-day, invitation-only conference that convenes approximately 250 biopharma CEOs, R&D executives, government officials, life science investors, and leading academics for off-the-record discussions

Join us for an Exclusive Premiere on What’s Next in Biotech with Gunderson Partner and Chair of Life Sciences Tim Ehrlich and Venrock Managing Partner Bryan Roberts

Gunderson Dettmer partner, Tim Ehrlich, to moderate a panel at the annual Genesis London Conference

Clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, Newleos Therapeutics, announces its $93.5 million Series A financing 

Global health company, Sherlock Biosciences, announces its acquisition by OraSure Technologies

Proximity-based therapeutics company, Photys Therapeutics, announces its multi-year collaboration and license agreement with Novo Nordisk

Forbes recognizes Gunderson Dettmer partner and chair of our Life Sciences practice group, Tim Ehrlich, in its 2025 America’s Top Lawyers list for healthcare law

LMG Life Sciences recognizes Gunderson Dettmer with Impact Deal of the Year and names Boston associate Joel Diamond the US Rising Star—Financial and Corporate in its 2025 Life Sciences Americas Awards

LMG Sciences shortlists Gunderson Dettmer and Boston associate Joel Diamond for the 2025 LMG Life Sciences Americas Awards